Yahoo
NasdaqGS - Nasdaq Real Time Price USD

Recursion Pharmaceuticals, Inc. (RXRX)

3.5200 +0.0200 (+0.57%)
At close: November 6 at 4:00:00 PM EST
3.5278 +0.0078 (+0.22%)
After hours: November 6 at 7:59:37 PM EST
Trade RXRX on Coinbase
View in AlphaSpace Currency in USD All numbers in thousands
Financial statements are getting an update on November 9
Preview it now to see what’s changing.
Learn more
Breakdown
TTM
12/31/2025
12/31/2024
12/31/2023
12/31/2022
Total Revenue
67,010
74,256
58,488
43,876
39,681
Cost of Revenue
48,301
70,953
45,238
42,587
48,275
Gross Profit
18,709
3,303
13,250
1,289
-8,594
Operating Expense
513,691
651,435
492,254
351,349
237,133
Operating Income
-494,982
-648,132
-479,004
-350,060
-245,727
Net Non Operating Interest Income Expense
21,418
20,978
14,186
19,019
6,199
Other Income Expense
-6,662
-17,741
30
-1,087
52
Pretax Income
-480,226
-644,895
-464,788
-332,128
-239,476
Tax Provision
-4,559
-136
-1,127
-4,062
0
Net Income Common Stockholders
-475,667
-644,759
-463,661
-328,066
-239,476
Diluted NI Available to Com Stockholders
-475,667
-644,759
-463,661
-328,066
-239,476
Basic EPS
-0.86
-1.44
-1.69
-1.58
-1.36
Diluted EPS
-0.86
-1.44
-1.69
-1.58
-1.36
Basic Average Shares
531,693.0100
447,446.1090
274,207.1460
207,853.7020
175,537.4870
Diluted Average Shares
531,693.0100
447,446.1090
274,207.1460
207,853.7020
175,537.4870
Total Operating Income as Reported
-494,982
-648,132
-479,004
-350,060
-245,727
Total Expenses
561,992
722,388
537,492
393,936
285,408
Net Income from Continuing & Discontinued Operation
-475,667
-644,759
-463,661
-328,066
-239,476
Normalized Income
-475,667
-644,759
-463,661
-328,066
-239,476
Interest Income
22,332
22,788
15,758
19,116
6,254
Interest Expense
914
1,810
1,572
97
55
Net Interest Income
21,418
20,978
14,186
19,019
6,199
EBIT
-479,312
-643,085
-463,216
-332,031
-239,421
EBITDA
-405,459
-559,384
-426,722
-307,629
-227,665
Reconciled Cost of Revenue
48,301
70,953
45,238
42,587
48,275
Reconciled Depreciation
73,853
83,701
36,494
24,402
11,756
Net Income from Continuing Operation Net Minority Interest
-475,667
-644,759
-463,661
-328,066
-239,476
Total Unusual Items Excluding Goodwill
--
--
--
0
0
Total Unusual Items
--
--
--
0
0
Normalized EBITDA
-405,459
-559,384
-426,722
-307,629
-227,665
Tax Rate for Calcs
0
0
0
0
0
Tax Effect of Unusual Items
0
0
0
0
0
12/31/2022 - 4/16/2021

Upgrade to begin using 40 years of financial statements and get so much more.

Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.

Upgrade

Related Tickers

Mobilize your Website
View Site in Mobile | Classic
Share by: